The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity or overweight following weight loss. This will be compared with the amount of energy used by participants who achieve weight loss through a low-calorie diet and by participants receiving placebo (without weight loss).
Male or female (sex assigned at birth, inclusive of all gender identities).
Age 18 years or older at the time of signing the informed consent.
Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.
Exposure to an investigational medicinal product within 30 days.
Any condition, or disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Anticipated change in lifestyle (e.g., eating, exercise or sleeping pattern) during the study, for example, an imminent job change to/from a physically demanding occupation.
Parallel
NNC0487-0111
DrugNNC0487-0111 will be administered subcutaneously.
Placebo
DrugPlacebo matched to NNC0487-0111 will be administered subcutaneously.
LED
BehavioralA meal plan and meal replacements will be provided by the investigators.
Change in sleeping metabolic rate (SMR)
Measured in kilojoules per day (kJ/day)
Change in 24-hour energy expenditure (EE)
Measured in kJ/day.
Change in basal metabolic rate (BMR)
Measured in kJ/day.
Change in resting metabolic rate (RMR)
Measured in kJ/day.
Change in diet-induced thermogenesis (DIT)
Measured in kJ/day.
Click on the lead sponsor to view all of their trials.
